EyeWorld Asia-Pacific September 2021 Issue

FEATURE EWAP SEPTEMBER 2021 11 -ignificantly, binocular contrast sensitivity was equivalent to contrast sensitivity in monofocal eyes even if monocularly contrast sensitivity in the IC-8 eyes was slightly reduced. Dr. Srinivasan said that the IC-8 IOL can tolerate up to 1.5 D of corneal cylinder and up to 1 D of deviation from target without compromise. e concluded that small aperture optic IOLs provide uninterrupted eÝtended depth of focus for cataract patients. e noted that targeting a small amount of myopia in the IC-8 IOL eye improves near, achieving a “low level of symptoms and high patient satisfaction.” Furthermore, he said that this IOL design has additional applications for challenging eyes (post-refractive, post-corneal transplant, and post-radial keratotomy eyes). The LAL One of the more striking IOL innovations is an IOL whose refractive power can be adjusted after implantation. Robert K. Maloney, MD, U.S., discussed the Light Adjustable Lens, an IOL made of a photosensitive material that changes power when eÝposed to ultraÛiolet light using a Light Delivery Device. At 2 weeks after implantation using any standard cataract surgery technique, the surgeon sits down with the patient to determine the best refractive target for them—emmetropia in both eyes? monovision? minimonovision? mild undercorrection? EDOF? “You can customize the vision in a way you never can with a non- adjustable lens because you can’t test any of this before surgery because they have a cataract,” Dr. Maloney said. e concluded that Ƃ is the most accurate IOL and allows customization of vision after cataract surgeryÆ the eÝtra effort necessary as the IOL power is locked in over several light treatments, he said, is manageable, and he believes The birth and growth of IOLs, beginning with the work of Sir Harold Ridley in 1949. Source: Chandra Bala, PhD, MBBS, FRANZCO that LAL has an important place in any cataract practice. “I can’t imagine a leading cataract practice that doesn’t offer this product,” he said. What would a surgeon choose? Wrapping up the symposium, Michael Lawless, MD, Australia, discussed which IOL he would have for himself given the options available in 2021. Dr. Lawless said that he is left eye dominant, with that eye at ÈÉÈ unaided. is nondominant right eye had previously undergone LASIK; the surgery aimed for –1.50 D for monovision, though having drifted over time is currently at –0.75 D corrected to 6/6. So: Good distance, happy to use reading glasses. aÛing had preÛious refractiÛe surgery, he has biometry and keratometry data available; he would use the Barrett True K TK for IOL power calculation. For his dominant eye, he would have a Clareon aspheric IOL (Alcon), aiming for plano, and for his nondominant eye, a Vivity aiming for –0.75 D. Editors’ note: Dr. Bala is a consultant for Alcon and Johnson and Johnson Vision. Dr. Auffarth has interests with various ophthalmic companies. Dr. Srinivasan is a consultant for AcuFocus. Dr. Maloney is an equity holder and consultant for RxSight. Dr. Lawless disclosed no relevant financial interests.